These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7990928)

  • 21. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
    Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
    J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine.
    Wallich R; Kramer MD; Simon MM
    Infection; 1996; 24(5):396-7. PubMed ID: 8923055
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaccination as a modality to prevent Lyme disease. A status report.
    Wormser GP
    Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid outer-surface protein C DNA tattoo vaccination protects against Borrelia afzelii infection.
    Wagemakers A; Mason LM; Oei A; de Wever B; van der Poll T; Bins AD; Hovius JW
    Gene Ther; 2014 Dec; 21(12):1051-7. PubMed ID: 25273355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi.
    Probert WS; Crawford M; Cadiz RB; LeFebvre RB
    J Infect Dis; 1997 Feb; 175(2):400-5. PubMed ID: 9203661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.
    Erdile LF; Guy B
    Vaccine; 1997 Jun; 15(9):988-96. PubMed ID: 9261945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New use of BCG for recombinant vaccines.
    Stover CK; de la Cruz VF; Fuerst TR; Burlein JE; Benson LA; Bennett LT; Bansal GP; Young JF; Lee MH; Hatfull GF
    Nature; 1991 Jun; 351(6326):456-60. PubMed ID: 1904554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evasion of protective immunity by Borrelia burgdorferi by truncation of outer surface protein B.
    Fikrig E; Tao H; Kantor FS; Barthold SW; Flavell RA
    Proc Natl Acad Sci U S A; 1993 May; 90(9):4092-6. PubMed ID: 7683420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine.
    Padilla ML; Callister SM; Schell RF; Bryant GL; Jobe DA; Lovrich SD; DuChateau BK; Jensen JR
    J Infect Dis; 1996 Oct; 174(4):739-46. PubMed ID: 8843211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel recombinant vaccinia virus-vectored vaccine affords complete protection against homologous
    Pfeifle A; Zhang W; Cao J; Thulasi Raman SN; Anderson-Duvall R; Tamming L; Gravel C; Coatsworth H; Chen W; Johnston MJW; Sauve S; Rosu-Myles M; Wang L; Li X
    Emerg Microbes Infect; 2024 Dec; 13(1):2399949. PubMed ID: 39221484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term protection of mice from Lyme disease by vaccination with OspA.
    Fikrig E; Barthold SW; Kantor FS; Flavell RA
    Infect Immun; 1992 Mar; 60(3):773-7. PubMed ID: 1541551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of protective borreliacidal antibodies in Lyme disease immunity and serodiagnosis.
    Callister SM; Schell RF
    J Infect Dis; 1994 Aug; 170(2):499-500. PubMed ID: 8035047
    [No Abstract]   [Full Text] [Related]  

  • 34. Lyme disease vaccine.
    Wormser GP
    Infection; 1996; 24(2):203-7. PubMed ID: 8740123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An effective vaccine against Lyme disease.
    Crooy P; Lobet Y
    J Biotechnol; 2000 Jan; 76(2-3):261-3. PubMed ID: 10656342
    [No Abstract]   [Full Text] [Related]  

  • 36. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection.
    Hanson MS; Cassatt DR; Guo BP; Patel NK; McCarthy MP; Dorward DW; Höök M
    Infect Immun; 1998 May; 66(5):2143-53. PubMed ID: 9573101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral vaccination of white-tailed deer using a recombinant Bacillus Calmette-Guérin vaccine expressing the Borrelia burgdorferi outer surface protein A: prospects for immunocontraception.
    Miller LA; Johns BE; Elias DJ; Killian GJ
    Am J Reprod Immunol; 1999 Apr; 41(4):279-85. PubMed ID: 10374705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Borrelia burgdorferi outer surface protein A vaccine: importance, role, and value.
    Sigal LH
    J Pediatr; 1999 Nov; 135(5):539-41. PubMed ID: 10547238
    [No Abstract]   [Full Text] [Related]  

  • 39. A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation.
    Palmer GA; Brogdon JL; Constant SL; Tattersall P
    J Virol; 2004 Feb; 78(3):1101-8. PubMed ID: 14722265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of immunization with recombinant lipoprotein outer surface protein a on serologic test for lyme disease.
    Fawcett PT; Rose CD; Maduskuie V
    Clin Diagn Lab Immunol; 2004 Jul; 11(4):808-10. PubMed ID: 15242965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.